Intravenous prostacyclin in acute nonhemorrhage stroke

A placebo-controlled double-blind trial

C. Y. Hsu, R. E. Faught, A. J. Furlan, Bruce M Coull, D. C. Huang, E. L. Hogan, O. I. Linet, F. M. Yatsu

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

The therapeutic efficacy of prostacyclin in nonhemorrhagic cerebral infarction was assessed in a placebo-controlled double-blind trial. A total of 80 patients with stroke onset within 24 hours were randomized into placebo (37 patients) and prostacyclin (43 patients) groups. Demographic data and risk factors were comparable. Patients in the prostacyclin group received a continuous i.v. infusion of prostacyclin at an average rate of 8.5 ng/kg/min for an average of 64 hours. The placebo group received vehicle only in a similar fashion. During treatment hemodynamic changes were more prominent in the patients receiving prostacyclin and included reduction of systolic and diastolic blood pressure and increase in pulse rate. In contrast there was only a slight (but significant) reduction of diastolic blood pressure in the placebo group. Neurologic deficit scores were determined on admission, at Day 3, and at Weeks 1, 2, and 4. Mean neurologic deficit scores upon entry were comparable in the placebo and prostacyclin groups, and a significant improvement in the score for neurologic deficit was noted in both. The placebo group tended to fare better throughout the study, with a significant difference in neurologic deficit score favoring the placebo group at Week 2 (p = 0.0048). Two patients in the placebo and one in the prostacyclin group died. The only difference in adverse reactions was flushing (6 patients in prostacyclin vs. 0 in placebo group, p < 0.05). The results of this study suggest a lack of therapeutic efficacy of prostacyclin in a defined population of patients with nonhemorrhagic cerebral infarction.

Original languageEnglish (US)
Pages (from-to)352-358
Number of pages7
JournalStroke
Volume18
Issue number2
StatePublished - 1987
Externally publishedYes

Fingerprint

Epoprostenol
Stroke
Placebos
Neurologic Manifestations
Blood Pressure
Cerebral Infarction
Therapeutics
Heart Rate
Hemodynamics
Demography

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

Hsu, C. Y., Faught, R. E., Furlan, A. J., Coull, B. M., Huang, D. C., Hogan, E. L., ... Yatsu, F. M. (1987). Intravenous prostacyclin in acute nonhemorrhage stroke: A placebo-controlled double-blind trial. Stroke, 18(2), 352-358.

Intravenous prostacyclin in acute nonhemorrhage stroke : A placebo-controlled double-blind trial. / Hsu, C. Y.; Faught, R. E.; Furlan, A. J.; Coull, Bruce M; Huang, D. C.; Hogan, E. L.; Linet, O. I.; Yatsu, F. M.

In: Stroke, Vol. 18, No. 2, 1987, p. 352-358.

Research output: Contribution to journalArticle

Hsu, CY, Faught, RE, Furlan, AJ, Coull, BM, Huang, DC, Hogan, EL, Linet, OI & Yatsu, FM 1987, 'Intravenous prostacyclin in acute nonhemorrhage stroke: A placebo-controlled double-blind trial', Stroke, vol. 18, no. 2, pp. 352-358.
Hsu CY, Faught RE, Furlan AJ, Coull BM, Huang DC, Hogan EL et al. Intravenous prostacyclin in acute nonhemorrhage stroke: A placebo-controlled double-blind trial. Stroke. 1987;18(2):352-358.
Hsu, C. Y. ; Faught, R. E. ; Furlan, A. J. ; Coull, Bruce M ; Huang, D. C. ; Hogan, E. L. ; Linet, O. I. ; Yatsu, F. M. / Intravenous prostacyclin in acute nonhemorrhage stroke : A placebo-controlled double-blind trial. In: Stroke. 1987 ; Vol. 18, No. 2. pp. 352-358.
@article{7a3d849dd7e04afc9ff72d48adaec358,
title = "Intravenous prostacyclin in acute nonhemorrhage stroke: A placebo-controlled double-blind trial",
abstract = "The therapeutic efficacy of prostacyclin in nonhemorrhagic cerebral infarction was assessed in a placebo-controlled double-blind trial. A total of 80 patients with stroke onset within 24 hours were randomized into placebo (37 patients) and prostacyclin (43 patients) groups. Demographic data and risk factors were comparable. Patients in the prostacyclin group received a continuous i.v. infusion of prostacyclin at an average rate of 8.5 ng/kg/min for an average of 64 hours. The placebo group received vehicle only in a similar fashion. During treatment hemodynamic changes were more prominent in the patients receiving prostacyclin and included reduction of systolic and diastolic blood pressure and increase in pulse rate. In contrast there was only a slight (but significant) reduction of diastolic blood pressure in the placebo group. Neurologic deficit scores were determined on admission, at Day 3, and at Weeks 1, 2, and 4. Mean neurologic deficit scores upon entry were comparable in the placebo and prostacyclin groups, and a significant improvement in the score for neurologic deficit was noted in both. The placebo group tended to fare better throughout the study, with a significant difference in neurologic deficit score favoring the placebo group at Week 2 (p = 0.0048). Two patients in the placebo and one in the prostacyclin group died. The only difference in adverse reactions was flushing (6 patients in prostacyclin vs. 0 in placebo group, p < 0.05). The results of this study suggest a lack of therapeutic efficacy of prostacyclin in a defined population of patients with nonhemorrhagic cerebral infarction.",
author = "Hsu, {C. Y.} and Faught, {R. E.} and Furlan, {A. J.} and Coull, {Bruce M} and Huang, {D. C.} and Hogan, {E. L.} and Linet, {O. I.} and Yatsu, {F. M.}",
year = "1987",
language = "English (US)",
volume = "18",
pages = "352--358",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Intravenous prostacyclin in acute nonhemorrhage stroke

T2 - A placebo-controlled double-blind trial

AU - Hsu, C. Y.

AU - Faught, R. E.

AU - Furlan, A. J.

AU - Coull, Bruce M

AU - Huang, D. C.

AU - Hogan, E. L.

AU - Linet, O. I.

AU - Yatsu, F. M.

PY - 1987

Y1 - 1987

N2 - The therapeutic efficacy of prostacyclin in nonhemorrhagic cerebral infarction was assessed in a placebo-controlled double-blind trial. A total of 80 patients with stroke onset within 24 hours were randomized into placebo (37 patients) and prostacyclin (43 patients) groups. Demographic data and risk factors were comparable. Patients in the prostacyclin group received a continuous i.v. infusion of prostacyclin at an average rate of 8.5 ng/kg/min for an average of 64 hours. The placebo group received vehicle only in a similar fashion. During treatment hemodynamic changes were more prominent in the patients receiving prostacyclin and included reduction of systolic and diastolic blood pressure and increase in pulse rate. In contrast there was only a slight (but significant) reduction of diastolic blood pressure in the placebo group. Neurologic deficit scores were determined on admission, at Day 3, and at Weeks 1, 2, and 4. Mean neurologic deficit scores upon entry were comparable in the placebo and prostacyclin groups, and a significant improvement in the score for neurologic deficit was noted in both. The placebo group tended to fare better throughout the study, with a significant difference in neurologic deficit score favoring the placebo group at Week 2 (p = 0.0048). Two patients in the placebo and one in the prostacyclin group died. The only difference in adverse reactions was flushing (6 patients in prostacyclin vs. 0 in placebo group, p < 0.05). The results of this study suggest a lack of therapeutic efficacy of prostacyclin in a defined population of patients with nonhemorrhagic cerebral infarction.

AB - The therapeutic efficacy of prostacyclin in nonhemorrhagic cerebral infarction was assessed in a placebo-controlled double-blind trial. A total of 80 patients with stroke onset within 24 hours were randomized into placebo (37 patients) and prostacyclin (43 patients) groups. Demographic data and risk factors were comparable. Patients in the prostacyclin group received a continuous i.v. infusion of prostacyclin at an average rate of 8.5 ng/kg/min for an average of 64 hours. The placebo group received vehicle only in a similar fashion. During treatment hemodynamic changes were more prominent in the patients receiving prostacyclin and included reduction of systolic and diastolic blood pressure and increase in pulse rate. In contrast there was only a slight (but significant) reduction of diastolic blood pressure in the placebo group. Neurologic deficit scores were determined on admission, at Day 3, and at Weeks 1, 2, and 4. Mean neurologic deficit scores upon entry were comparable in the placebo and prostacyclin groups, and a significant improvement in the score for neurologic deficit was noted in both. The placebo group tended to fare better throughout the study, with a significant difference in neurologic deficit score favoring the placebo group at Week 2 (p = 0.0048). Two patients in the placebo and one in the prostacyclin group died. The only difference in adverse reactions was flushing (6 patients in prostacyclin vs. 0 in placebo group, p < 0.05). The results of this study suggest a lack of therapeutic efficacy of prostacyclin in a defined population of patients with nonhemorrhagic cerebral infarction.

UR - http://www.scopus.com/inward/record.url?scp=0023253536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023253536&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 352

EP - 358

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 2

ER -